PURPOSE: Zymosan-induced generalized inflammation is the only experimental model that reproduces characteristics of human multiple organ dysfunction syndrome (MODS). Toll-like receptors (TLRs) are key components in innate immune responses and their signaling pathway is known to activate target genes such as nuclear factor-κB (NF-κB) and cytokines that are involved in inflammation and immune responses. We previously reported that hyperbaric oxygen (HBO) therapy is effective in the treatment of severe zymosan-induced inflammation in MODS. The aim of this study was to investigate the effect of HBO exposure on TLR2 and TLR4 signal transduction and organ dysfunction during MODS induced by zymosan in the rat. METHODS: Male Wistar rats were randomized into four groups and treated as follows: (1) saline solution (control); (2) zymosan; (3) HBO 4 and 11 h after zymosan injection; (4) HBO 4 and 11 h after saline solution injection. Zymosan-induced damage of the lungs, liver, and small intestine was evaluated using histology and biochemistry. The activation of the TLR signaling pathway was measured with Western blot, reverse transcriptase polymerase chain reaction analysis (RT-PCR), and immunohistochemistry. RESULTS: Zymosan induced a severe inflammatory response characterized by the activation of the TLR signaling pathway and by an organ dysfunction. HBO exposure significantly reduced the development of lung, liver, and intestine injury in our experimental model. It also significantly reduced the zymosan-induced expression of TLR2 and TLR4, NF-κB activation, and cytokine production. CONCLUSIONS: Taken together, these results suggest that, by interfering with the TLR pathway, HBO treatment may exert a protective effect against tissue injury caused by zymosan-induced generalized inflammation.
PURPOSE:Zymosan-induced generalized inflammation is the only experimental model that reproduces characteristics of human multiple organ dysfunction syndrome (MODS). Toll-like receptors (TLRs) are key components in innate immune responses and their signaling pathway is known to activate target genes such as nuclear factor-κB (NF-κB) and cytokines that are involved in inflammation and immune responses. We previously reported that hyperbaric oxygen (HBO) therapy is effective in the treatment of severe zymosan-induced inflammation in MODS. The aim of this study was to investigate the effect of HBO exposure on TLR2 and TLR4 signal transduction and organ dysfunction during MODS induced by zymosan in the rat. METHODS: Male Wistar rats were randomized into four groups and treated as follows: (1) saline solution (control); (2) zymosan; (3) HBO 4 and 11 h after zymosan injection; (4) HBO 4 and 11 h after saline solution injection. Zymosan-induced damage of the lungs, liver, and small intestine was evaluated using histology and biochemistry. The activation of the TLR signaling pathway was measured with Western blot, reverse transcriptase polymerase chain reaction analysis (RT-PCR), and immunohistochemistry. RESULTS:Zymosan induced a severe inflammatory response characterized by the activation of the TLR signaling pathway and by an organ dysfunction. HBO exposure significantly reduced the development of lung, liver, and intestine injury in our experimental model. It also significantly reduced the zymosan-induced expression of TLR2 and TLR4, NF-κB activation, and cytokine production. CONCLUSIONS: Taken together, these results suggest that, by interfering with the TLR pathway, HBO treatment may exert a protective effect against tissue injury caused by zymosan-induced generalized inflammation.
Authors: Robert P Ostrowski; Gerhart Graupner; Elena Titova; Jennifer Zhang; Jeffrey Chiu; Neal Dach; Dalia Corleone; Jiping Tang; John H Zhang Journal: Neurobiol Dis Date: 2007-07-28 Impact factor: 5.996
Authors: A Poltorak; X He; I Smirnova; M Y Liu; C Van Huffel; X Du; D Birdwell; E Alejos; M Silva; C Galanos; M Freudenberg; P Ricciardi-Castagnoli; B Layton; B Beutler Journal: Science Date: 1998-12-11 Impact factor: 47.728
Authors: S Cuzzocrea; F Imperatore; G Costantino; C Luongo; E Mazzon; M A Scafuro; G Mangoni; A P Caputi; F Rossi; A Filippelli Journal: Shock Date: 2000-03 Impact factor: 3.454
Authors: Francesco Imperatore; Salvatore Cuzzocrea; Carlo Luongo; Giovanni Liguori; Antonella Scafuro; Antonella De Angelis; Francesco Rossi; Achille P Caputi; Amelia Filippelli Journal: Intensive Care Med Date: 2004-02-12 Impact factor: 17.440
Authors: Salvatore Cuzzocrea; Prabal K Chatterjee; Emanuela Mazzon; Ivana Serraino; Laura Dugo; Tommaso Centorrino; Alberto Barbera; Antonio Ciccolo; Francesco Fulia; Michelle C McDonald; Achille P Caputi; Christoph Thiemermann Journal: Crit Care Med Date: 2002-10 Impact factor: 7.598
Authors: Simona Zarini; Miguel A Gijón; Aaron E Ransome; Robert C Murphy; Angelo Sala Journal: Proc Natl Acad Sci U S A Date: 2009-05-04 Impact factor: 11.205
Authors: Chai R Soh; Ricardo Pietrobon; John J Freiberger; Sophia T Chew; Dimple Rajgor; Mihir Gandhi; Jatin Shah; Richard E Moon Journal: Intensive Care Med Date: 2012-04-20 Impact factor: 17.440
Authors: Ashley M Fuller; Charles Giardina; Lawrence E Hightower; George A Perdrizet; Cassandra A Tierney Journal: Cell Stress Chaperones Date: 2012-08-03 Impact factor: 3.667
Authors: Matteo Paganini; Gerardo Bosco; Filippo A G Perozzo; Eva Kohlscheen; Regina Sonda; Franco Bassetto; Giacomo Garetto; Enrico M Camporesi; Stephen R Thom Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622
Authors: Massimo Antonelli; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; J Randall Curtis; Daniel De Backer; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Patricia Rocco; Jean-François Timsit; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2012-01-04 Impact factor: 17.440